Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420873 · ClinicalTrials.gov registry record · Phase 2
An Open-label Phase II Study of Lorvotuzumab Mertansine
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02420873: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02420873 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420873, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.
Interventions
- DRUG Lorvotuzumab Mertansine (IMGN901)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-05-12 |
| Est. Completion | 2017-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420873
The ClinicalTrials.gov registry entry for NCT02420873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lorvotuzumab Mertansine (IMGN901) is the first listed.
NCT02420873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420873 about?
NCT02420873 is a clinical study titled "An Open-label Phase II Study of Lorvotuzumab Mertansine". The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.
What is the current status of trial NCT02420873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-05-12. Estimated completion is 2017-06-06.
What interventions are being tested in trial NCT02420873?
The interventions under investigation include: Lorvotuzumab Mertansine (IMGN901) (DRUG).
Who is sponsoring clinical trial NCT02420873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.